- Home
- BIIB vs BNTX Comparison
BIIB vs BNTX Comparison
Compare BIIB & BNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- BNTX
- Stock Information
- Founded
- BIIB 1978
- BNTX 2008
- Country
- BIIB United States
- BNTX Germany
- Employees
- BIIB N/A
- BNTX N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- BNTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BIIB Health Care
- BNTX Health Care
- Exchange
- BIIB Nasdaq
- BNTX Nasdaq
- Market Cap
- BIIB 25.1B
- BNTX 23.9B
- IPO Year
- BIIB 1991
- BNTX 2019
- Fundamental
- Price
- BIIB $159.17
- BNTX $117.39
- Analyst Decision
- BIIB Buy
- BNTX Strong Buy
- Analyst Count
- BIIB 25
- BNTX 14
- Target Price
- BIIB $258.57
- BNTX $141.60
- AVG Volume (30 Days)
- BIIB 1.6M
- BNTX 1.1M
- Earning Date
- BIIB 10-30-2024
- BNTX 11-04-2024
- Dividend Yield
- BIIB N/A
- BNTX N/A
- EPS Growth
- BIIB 10.05
- BNTX N/A
- EPS
- BIIB 11.06
- BNTX N/A
- Revenue
- BIIB $9,607,500,000.00
- BNTX $3,390,698,192.00
- Revenue This Year
- BIIB N/A
- BNTX N/A
- Revenue Next Year
- BIIB N/A
- BNTX N/A
- P/E Ratio
- BIIB $14.55
- BNTX N/A
- Revenue Growth
- BIIB N/A
- BNTX N/A
- 52 Week Low
- BIIB $153.62
- BNTX $76.53
- 52 Week High
- BIIB $268.30
- BNTX $131.49
- Technical
- Relative Strength Index (RSI)
- BIIB 41.81
- BNTX 54.22
- Support Level
- BIIB $159.12
- BNTX $101.02
- Resistance Level
- BIIB $165.29
- BNTX $121.80
- Average True Range (ATR)
- BIIB 3.25
- BNTX 4.75
- MACD
- BIIB 1.25
- BNTX 0.75
- Stochastic Oscillator
- BIIB 70.36
- BNTX 77.76
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.